Proportion of participants with endophthalmitis · people with neovascular age‐related macular degeneration
Extended‐fixed showed no clear difference in endophthalmitis (ocular adverse event) compared with monthly injections (low certainty).
1 finding from 1 review
Change in BCVA at 1 year (ETDRS letters score, the higher the score the better) · people with neovascular age‐related macular degeneration
1 finding from 1 review
Gain of 3 or more lines of visual acuity · people with neovascular age‐related macular degeneration
Extended‐fixed showed no clear difference in gain of ≥ 15 letters visual acuity at 1 year compared with monthly injections (moderate certainty).
1 finding from 1 review
Overall survival
Extended‐field radiotherapy probably leads to lower overall survival compared with pelvic radiotherapy (moderate certainty).
1 finding from 1 review
Para‐aortic lymph node recurrence
Extended‐field radiotherapy probably leads to lower para‐aortic lymph node recurrence compared with pelvic radiotherapy (moderate certainty).
1 finding from 1 review
Progression‐free survival
Extended‐field radiotherapy showed no clear difference in progression‐free survival compared with pelvic radiotherapy (moderate certainty).
1 finding from 1 review
Adverse events
Extended‐field radiotherapy showed no clear difference in adverse events compared with pelvic radiotherapy (moderate certainty).
1 finding from 1 review
Overall survival
Extended‐field radiotherapy probably leads to lower overall survival compared with pelvic chemoradiotherapy (moderate certainty).
1 finding from 1 review
Para‐aortic lymph node recurrence
Extended‐field radiotherapy may leads to lower para‐aortic lymph node recurrence compared with pelvic chemoradiotherapy (low certainty).
1 finding from 1 review
Progression‐free survival
Extended‐field radiotherapy probably leads to lower progression‐free survival compared with pelvic chemoradiotherapy (moderate certainty).
1 finding from 1 review
Acute adverse events
Extended‐field radiotherapy probably leads to lower acute adverse events compared with pelvic chemoradiotherapy (moderate certainty).
1 finding from 1 review
Late adverse events
Extended‐field radiotherapy showed no clear difference in late adverse events compared with pelvic chemoradiotherapy (moderate certainty).
1 finding from 1 review
Days missed from work or school · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
ADHD symptoms · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
3 findings from 1 review
no estimate extracted
16 studies · 3799 participants
Very low
no estimate extracted
18 studies · 4183 participants
Very low
no estimate extracted
3 studies · 1005 participants
Very low
Serious adverse events Median · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
Quality of life, self‐rated at post‐treatment · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
Proportion of participants experiencing adverse events · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
Overall survival
It is very uncertain whether extended‐field chemoradiotherapy changes overall survival compared with pelvic chemoradiotherapy (very low certainty).
1 finding from 1 review
Para‐aortic lymph node recurrence
It is very uncertain whether extended‐field chemoradiotherapy changes para‐aortic lymph node recurrence compared with pelvic chemoradiotherapy (very low certainty).
1 finding from 1 review
Progression‐free survival
It is very uncertain whether extended‐field chemoradiotherapy changes progression‐free survival compared with pelvic chemoradiotherapy (very low certainty).
1 finding from 1 review